## Data Form for Cancer Staging
### SOFT TISSUE SARCOMA STAGING FORM

<table>
<thead>
<tr>
<th>Clinical</th>
<th>Stage Category Definitions</th>
<th>Pathologic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extent of disease before any treatment</td>
<td></td>
<td>Extent of disease during and from surgery</td>
</tr>
<tr>
<td>□ y clinical-staging completed after neoadjuvant therapy but before subsequent surgery</td>
<td>□ Tumor size: _________</td>
<td>□ y pathologic-staging completed after neoadjuvant therapy AND subsequent surgery</td>
</tr>
<tr>
<td></td>
<td>Laterality □ Left □ Right □ Bilateral</td>
<td></td>
</tr>
</tbody>
</table>

### PRIMARY TUMOR (T)
- □ TX: Primary tumor cannot be assessed
- □ T0: No evidence of primary tumor
- □ T1: Tumor 5 cm or less in greatest dimension
  - Superficial tumor
  - Deep tumor
- □ T2: Tumor more than 5 cm in greatest dimension
  - Superficial tumor
  - Deep tumor

Note: Superficial tumor is located exclusively above the superficial fascia without invasion of the fascia; deep tumor is located either exclusively beneath the superficial fascia, superficial to the fascia with invasion of or through the fascia, or both superficial yet beneath the fascia.

### REGIONAL LYMPH NODES (N)
- □ NX: Regional lymph nodes cannot be assessed
- □ N0: No regional lymph node metastasis
- □ N1*: Regional lymph node metastasis

*Note: Presence of positive nodes (N1) in N0 tumors is considered Stage III

### DISTANT METASTASIS (M)
- □ M0: No distant metastasis (no pathologic M0; use clinical M to complete stage group)
- □ M1: Distant metastasis

### ANATOMIC STAGE • PROGNOSTIC GROUPS

#### CLINICAL

<table>
<thead>
<tr>
<th>GROUP</th>
<th>T</th>
<th>N</th>
<th>M</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
<td>G1, GX</td>
</tr>
<tr>
<td>IB</td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
<td>G1, GX</td>
</tr>
<tr>
<td>IIA</td>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
<td>G2, G3</td>
</tr>
<tr>
<td>IIb</td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
<td>G2</td>
</tr>
<tr>
<td>III</td>
<td>T2a, T2b</td>
<td>N0</td>
<td>M0</td>
<td>G3</td>
</tr>
<tr>
<td>IV</td>
<td>Any T</td>
<td>N1</td>
<td>M0</td>
<td>Any G</td>
</tr>
</tbody>
</table>

#### PATHOLOGIC

<table>
<thead>
<tr>
<th>GROUP</th>
<th>T</th>
<th>N</th>
<th>M</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
<td>G1, GX</td>
</tr>
<tr>
<td>IB</td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
<td>G1, GX</td>
</tr>
<tr>
<td>IIA</td>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
<td>G2, G3</td>
</tr>
<tr>
<td>IIb</td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
<td>G2</td>
</tr>
<tr>
<td>III</td>
<td>T2b</td>
<td>N0</td>
<td>M0</td>
<td>G3</td>
</tr>
<tr>
<td>IV</td>
<td>Any T</td>
<td>N1</td>
<td>M0</td>
<td>Any G</td>
</tr>
</tbody>
</table>

| Stage unknown |

---

American Joint Committee on Cancer 2010

Form No: MR0074
EC App 12/97 Revised EC 05/10
Page 1 of 3
### Data Form for Cancer Staging

**SOFT TISSUE SARCOMA STAGING FORM**

**NAME:** ___________________________________

**MRN:** _______________________

---

#### PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)

**REQUIRED FOR STAGING:** Grade

**CLINICALLY SIGNIFICANT:**
- Neurovascular invasion as determined by pathology:
- Bone invasion as determined by imaging:
- If Pm1, source of pathologic metastatic specimen:

**Histologic Grade (G) (also known as overall grade)**

<table>
<thead>
<tr>
<th>Grading system</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 grade system</td>
<td>Grade I or 1</td>
</tr>
<tr>
<td>3 grade system</td>
<td>Grade II or 2</td>
</tr>
<tr>
<td>4 grade system</td>
<td>Grade III or 3</td>
</tr>
<tr>
<td>No 2, 3, or 4 grade system is available</td>
<td>Grade IV or 4</td>
</tr>
</tbody>
</table>

#### ADDITIONAL DESCRIPTORS

**Lymphatic Vessel Invasion (L) and Venous Invasion (V)** have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists’ (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.

- Lymph-Vascular Invasion Not Present (absent)/Not Identified
- Lymph-Vascular Invasion Present/Identified
- Not Applicable
- Unknown/Indeterminate

**Residual Tumor (R)**
The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy, there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

- RX Presence of residual tumor cannot be assessed
- R0 No residual tumor
- R1 Microscopic residual tumor
- R2 Macroscopic residual tumor

---

General Notes:
- For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y", "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.
- m suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.
- y prefix indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a "y" prefix. The ypTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy.
- r prefix indicates a recurrent tumor when staged after a disease-free interval, and is identified by the "r" prefix: rTNM.
- a prefix designates the stage determined at autopsy: aTNM.
- Surgical margins in data field recorded by registrars describing the surgical margins of the resected primary site specimen as determined only by the pathology report.
- neoadjuvant treatment is radiation therapy or systemic therapy (consisting of chemotherapy, hormone therapy, or immunotherapy) administered prior to a definitive surgical procedure. If the surgical procedure is not performed, the administered therapy no longer meets the definition of neoadjuvant therapy.

- Clinical stage was used in treatment planning (describe):

- National guidelines were used in treatment planning

---

**Physician signature**

**Date/Time**